412327-07-2

Basic information

• Product Name: 4-Methoxybenzylhydrazine dihydrochloride
• Synonyms: (4-Methoxyphenyl)Methyl]-hydrazine dichlorhydrate;[(4-methoxyphenyl)methyl]hydrazine dihydrochloride;1-(4-Methoxybenzyl)hydrazine dihydrochloride;Hydrazine, [(4-methoxyphenyl)methyl]-, hydrochloride (1:2);(4-METHOXYBENZYL)HYDRAZINE HCL;(4-METHOXYBENZYL)HYDRAZINE 2HCL
• CAS NO: 412327-07-2
• Molecular Formula: C8H14Cl2N2O
• Molecular Weight: 225.11556
• Mol File: 412327-07-2.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 4-Methoxybenzylhydrazine dihydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Methoxybenzylhydrazine dihydrochloride(412327-07-2)
• EPA Substance Registry System: 4-Methoxybenzylhydrazine dihydrochloride(412327-07-2)

Safety Data

• Hazardous Substances Data: 412327-07-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Methoxybenzylhydrazine dihydrochloride is used as a key intermediate for the synthesis of heterocyclic derivatives that are useful as SHP2 inhibitors. SHP2 is a non-receptor protein tyrosine phosphatase that plays a crucial role in cellular signaling pathways. Inhibition of SHP2 has been shown to have therapeutic potential in various diseases, including cancer and inflammatory disorders.
4-Methoxybenzylhydrazine dihydrochloride's ability to form heterocyclic derivatives with SHP2 inhibitory properties makes it a valuable asset in the development of novel therapeutic agents. By incorporating 4-Methoxybenzylhydrazine dihydrochloride into the synthesis process, researchers can create new molecules with improved potency, selectivity, and pharmacokinetic properties, ultimately leading to more effective treatments for patients.

Upstream product

• 824-94-2 p-methoxybenzyl chloride 
• 150767-02-5 N-1-(tert-butoxycarbonyl)-N-2-<(4-methoxyphenyl)methyl>hydrazine 
• 123-11-5 4-methoxy-benzaldehyde 

Downstream Products

• 1370448-79-5 1-(4-hydroxy-1-(4-methoxybenzyl)-1H-pyrazol-3-yl)ethan-1-one 
• 1617523-31-5 C₂₂H₂₄N₂O₅ 
• 949556-61-0 1-(4-methoxybenzyl)-3-methyl-1H-pyrazol-5-amine 
• 1152526-72-1 1-(4-methoxybenzyl)-4-methyl-1H-pyrazol-5-amine 

Relevant articles and documents

6H-THIENO[2,3-E][1,2,4]TRIAZOLO[3,4-C][1,2,4]TRIAZEPINE DERIVATIVE

The 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivatives or salts thereof of the present invention have BRD4 inhibitory activity, and thus, they are useful as medicaments, in particular, as prophylaxis and/or therapeutic agents for diseases associated with BRD4.

EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS

The present invention is directed to substituted pyridizinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS

The present invention is directed to substituted pyridizinone compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Development and a practical synthesis of the JAK2 inhibitor LY2784544

The route selection and process research and development of a practical synthesis for JAK2 inhibitor LY2784544 is described. The first-generation synthesis route, similar to that used in discovery for derivatization of a benzylic amine moiety, was 14 overall steps and possessed several steps that required extensive development for large-scale production. Route selection considerations led to a modified synthesis that utilized a novel vanadium-catalyzed carbon-carbon bond-forming arylation reaction for incorporation of the key benzylic morpholine moiety. A protecting group used to mask an amino pyrazole unit was modified from PMB to tert-butyl, resulting in a dramatic reduction in the overall length of the route. These two major changes resulted in an eight-step synthesis, which was six steps shorter than the first-generation synthesis. In the pilot plant, the new synthesis was scaled to produce >100 kg of LY2784544 in high yield and purity under GMP conditions. The overall development including the vanadium-catalyzed C-C bond-forming methodology, a ketone reductive deoxygenation, and a palladium-catalyzed amination is described.

HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE

The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.

AMINO PYRAZOLE COMPOUND

The present invention provides amino pyrazole compounds useful in the treatment of chronic myeloproliferative disorders and various cancers, e.g., glioblastoma, breast cancer, multiple myeloma, prostate cancer, and leukemias.

HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE

The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.

Anti-HIV pyrazole derivatives

The present invention comprises novel and known pyrazole derivatives having anti-HIV activity, a process for their manufacture, pharmaceutical compositions and the use of such compounds in medicine. In particular, the compounds of formula I are inhibitors

CYTOKINE PRODUCTION INHIBITORS, TRIAZEPINE COMPOUNDS, AND INTERMEDIATES THEREOF

The present invention relates to a cytokine production inhibitor comprising a compound of the formula [I] wherein R1is aryl or heteroaryl; B is a group of the formula (a) or (b) wherein R2is hydrogen atom, hydroxy, halogen atom and t